Risk Factors and Outcomes of Recurrent Candidemia in Children: Relapse or Re-Infection?
- PMID: 30654524
- PMCID: PMC6352033
- DOI: 10.3390/jcm8010099
Risk Factors and Outcomes of Recurrent Candidemia in Children: Relapse or Re-Infection?
Abstract
In this paper, our aim was to investigate the incidence, clinical characteristics, risk factors, and outcomes of recurrent candidemia in children. We retrospectively reviewed all children with candidemia from a medical center in Taiwan between 2004 and 2015. Two episodes of candidemia ≥30 days apart with clinical and microbiological resolution in the interim were defined as "late recurrence", and those that had 8⁻29 days apart from previous episodes were defined as "early recurrence". 45 patients (17.2%) had 57 episodes of recurrent candidemia, and 24 had 28 episodes of late recurrent candidemia. The median time between recurrences was 1.8 months (range: <1 month to 13 months). Of those, 29 had relapsed candidemia and 28 were re-infected by different Candida species (n = 24) or by different strains (n = 4). Recurrent candidemia patients were more likely to require echinocandins treatment, had a longer duration of candidemia, and higher rate of treatment failure (p = 0.001, 0.014, and 0.012, respectively). Underlying gastrointestinal diseases (Odds ratio (OR) 3.84; 95% Confidence interval (CI) 1.81⁻8.12) and neurological sequelae (OR 2.32; 95% CI 1.15⁻4.69) were independently associated with the development of recurrent candidemia. 17.2% of pediatric patients with candidemia developed recurrent candidemia, and approximately half were re-infected. Underlying gastrointestinal diseases and neurological sequelae were the independent risk factors for recurrent candidemia.
Keywords: antifungal resistance; late-onset sepsis; premature infants; recurrent candidemia.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Factors and outcomes associated with candidemia caused by non-albicans Candida spp versus Candida albicans in children.Am J Infect Control. 2018 Dec;46(12):1387-1393. doi: 10.1016/j.ajic.2018.05.015. Epub 2018 Aug 9. Am J Infect Control. 2018. PMID: 30100260
-
Risk factors for late recurrent candidaemia. A retrospective matched case-control study.Clin Microbiol Infect. 2016 Mar;22(3):277.e11-20. doi: 10.1016/j.cmi.2015.10.023. Epub 2015 Nov 5. Clin Microbiol Infect. 2016. PMID: 26548507
-
Clinical and microbiological characteristics, and impact of therapeutic strategies on the outcomes of children with candidemia.Sci Rep. 2017 Apr 24;7(1):1083. doi: 10.1038/s41598-017-01123-6. Sci Rep. 2017. PMID: 28439070 Free PMC article.
-
Candida and candidaemia. Susceptibility and epidemiology.Dan Med J. 2013 Nov;60(11):B4698. Dan Med J. 2013. PMID: 24192246 Review.
-
Candidemia in a pediatric population.Clin Infect Dis. 1995 Mar;20(3):571-5. doi: 10.1093/clinids/20.3.571. Clin Infect Dis. 1995. PMID: 7756477 Review.
Cited by
-
Candida auris vs. Non-Candida auris Candidemia in Critically Ill Patients: Clinical Outcomes, Risk Factors, and Mortality.J Fungi (Basel). 2025 Jul 24;11(8):552. doi: 10.3390/jof11080552. J Fungi (Basel). 2025. PMID: 40863504 Free PMC article.
-
Combination Therapy to Treat Fungal Biofilm-Based Infections.Int J Mol Sci. 2020 Nov 23;21(22):8873. doi: 10.3390/ijms21228873. Int J Mol Sci. 2020. PMID: 33238622 Free PMC article. Review.
-
Growing importance of urogenital candidiasis in individuals with diabetes: A narrative review.World J Diabetes. 2022 Oct 15;13(10):809-821. doi: 10.4239/wjd.v13.i10.809. World J Diabetes. 2022. PMID: 36311997 Free PMC article. Review.
-
Short Course of Antifungal Therapy in Patients With Uncomplicated Candida Bloodstream Infection: Another Case of Less Is More in the Clinical Setting?Open Forum Infect Dis. 2022 Dec 8;10(1):ofac656. doi: 10.1093/ofid/ofac656. eCollection 2023 Jan. Open Forum Infect Dis. 2022. PMID: 36655192 Free PMC article.
-
Pediatric Candida Bloodstream Infections Complicated with Mixed and Subsequent Bacteremia: The Clinical Characteristics and Impacts on Outcomes.J Fungi (Basel). 2022 Oct 31;8(11):1155. doi: 10.3390/jof8111155. J Fungi (Basel). 2022. PMID: 36354922 Free PMC article.
References
-
- Fernadez-Ruiz M., Guinea J., Lora-Pablos D., Zaragoza O., Puig-Asensio M., Almirante B., Cuenca-Estrella M., Aguado J.M. Impact of fluconazole susceptibility on the outcome of patients with candidemia: Data from a population-based surveillance. Clin. Microbiol. Infect. 2017;23:672. - PubMed
-
- Montravers P., Perrigault P.F., Timsit J.F., Mira J.P., Lortholary O., Leroy O., Gangneux J.P., Guillemot D., Bensoussan C., Bailly S., et al. Antifungal therapy for patients with proven or suspected Candida peritonitis: Amarcand, a prospective cohort study in French intensive care units. Clin. Microbiol. Infect. 2017;23:117. doi: 10.1016/j.cmi.2016.10.001. - DOI - PubMed
-
- Hesstvedt L., Gaustad P., Andersen C.T., Haarr E., Hannula R., Haukland H.H., Hermansen N.O., Larssen K.W., Mylvaganam H., Ranheim T.E., et al. Twenty-two years of candidaemia surveillance: Results from a Norwegian national study. Clin. Microbiol. Infect. 2015;21:938–945. doi: 10.1016/j.cmi.2015.06.008. - DOI - PubMed
-
- Tsai M.H., Wang S.H., Hsu J.F., Lin L.C., Chu S.M., Huang H.R., Chiang M.C., Fu R.H., Lu J.J., Huang Y.C. Clinical and molecular characteristics of bloodstream infections caused by Candida albicans in children from 2003 to 2011. Clin. Microbiol. Infect. 2015;21:1018. doi: 10.1016/j.cmi.2015.06.024. - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources